178 related articles for article (PubMed ID: 1503352)
1. Zidovudine: five years later.
McLeod GX; Hammer SM
Ann Intern Med; 1992 Sep; 117(6):487-501. PubMed ID: 1503352
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Kamali F
Clin Investig; 1993 May; 71(5):392-405. PubMed ID: 7685214
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
[TBL] [Abstract][Full Text] [Related]
4. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC; Peters DH; Faulds D
Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
[TBL] [Abstract][Full Text] [Related]
5. Current perspectives on antiretroviral therapy.
Fletcher CV
Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
Bozzette SA; Richman DD
Am J Med; 1990 May; 88(5B):24S-26S. PubMed ID: 2159706
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine (Retrovir) update.
Rachlis AR
CMAJ; 1990 Dec; 143(11):1177-85. PubMed ID: 2224694
[TBL] [Abstract][Full Text] [Related]
8. AIDS: Part II.
Kessler HA; Bick JA; Pottage JC; Benson CA
Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Wilde MI; Langtry HD
Drugs; 1993 Sep; 46(3):515-578. PubMed ID: 7693435
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus infection in children.
Hoernle EH; Reid TE
Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
17. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Bhana N; Ormrod D; Perry CM; Figgitt DP
Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
[TBL] [Abstract][Full Text] [Related]
19. [Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
Jost J; Lüthy R
Schweiz Med Wochenschr; 1991 Apr; 121(16):555-65. PubMed ID: 1904164
[TBL] [Abstract][Full Text] [Related]
20. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
